In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) was $23.15 for the day, down -4.10% from the previous closing price of $24.14. In other words, the price has decreased by -$4.10 from its previous closing price. On the day, 1.46 million shares were traded. APLS stock price reached its highest trading level at $23.93 during the session, while it also had its lowest trading level at $23.1.
Ratios:
Our analysis of APLS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.87 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 662.95. For the most recent quarter (mrq), Quick Ratio is recorded 3.16 and its Current Ratio is at 3.77. In the meantime, Its Debt-to-Equity ratio is 3.01 whereas as Long-Term Debt/Eq ratio is at 2.96.
On May 09, 2025, Raymond James Downgraded its rating to Outperform which previously was Strong Buy but kept the price unchanged to $52.
BofA Securities Downgraded its Buy to Neutral on May 09, 2025, while the target price for the stock was maintained at $23.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 30 ’25 when Dunlop A. Sinclair sold 31,092 shares for $22.58 per share. The transaction valued at 702,057 led to the insider holds 33,979 shares of the business.
Dunlop A. Sinclair sold 31,092 shares of APLS for $713,561 on Sep 19 ’25. The Director now owns 68,908 shares after completing the transaction at $22.95 per share. On Sep 19 ’25, another insider, Dunlop A. Sinclair, who serves as the Director of the company, bought 93,276 shares for $22.95 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLS now has a Market Capitalization of 2923611392 and an Enterprise Value of 3018596352. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.87 while its Price-to-Book (P/B) ratio in mrq is 18.69. Its current Enterprise Value per Revenue stands at 4.0 whereas that against EBITDA is -16.034.
Stock Price History:
The Beta on a monthly basis for APLS is 0.69, which has changed by -0.17173523 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, APLS has reached a high of $35.72, while it has fallen to a 52-week low of $16.10. The 50-Day Moving Average of the stock is -8.45%, while the 200-Day Moving Average is calculated to be -0.85%.
Shares Statistics:
APLS traded an average of 2.45M shares per day over the past three months and 2239470 shares per day over the past ten days. A total of 126.19M shares are outstanding, with a floating share count of 104.36M. Insiders hold about 17.37% of the company’s shares, while institutions hold 101.13% stake in the company. Shares short for APLS as of 1759190400 were 21047108 with a Short Ratio of 8.59, compared to 1756425600 on 20539985. Therefore, it implies a Short% of Shares Outstanding of 21047108 and a Short% of Float of 21.95.
Earnings Estimates
Investors are keenly observing as 12.0 analysts analyze and rate . The current performance of Apellis Pharmaceuticals Inc (APLS) in the stock market.The consensus estimate for the next quarter is -$0.33, with high estimates of $0.22 and low estimates of -$0.61.
Analysts are recommending an EPS of between $0.65 and -$2.29 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is -$1.11, with 12.0 analysts recommending between $0.45 and -$2.24.
Revenue Estimates
It is expected that $90B in revenue will be generated in . The current quarter, according to 18 analysts. It ranges from a high estimate of $465M to a low estimate of $178M. As of . The current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $196.83MFor the next quarter, 18 analysts are estimating revenue of $210.65M. There is a high estimate of $283M for the next quarter, whereas the lowest estimate is $182.1M.
A total of 19 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $1.03B, while the lowest revenue estimate was $705.4M, resulting in an average revenue estimate of $925.74M. In the same quarter a year ago, actual revenue was $781.37MBased on 19 analysts’ estimates, the company’s revenue will be $900.81M in the next fiscal year. The high estimate is $1.02B and the low estimate is $757.8M.
